Anzeige
Mehr »
Login
Sonntag, 03.07.2022 Börsentäglich über 12.000 News von 664 internationalen Medien
Breaking News! Geniale Übernahme - NFT Technologies im Fokus der Anleger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 936386 ISIN: US8006771062 Ticker-Symbol: GBY 
Tradegate
01.07.22
16:55 Uhr
4,085 Euro
-0,015
-0,35 %
1-Jahres-Chart
SANGAMO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SANGAMO THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,0684,15002.07.
4,0544,14501.07.

Aktuelle News zur SANGAMO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.06.Sangamo Therapeutics begun at neutral at Wedbush on 'frontrunner' Fabry candidate22
SANGAMO THERAPEUTICS Aktie jetzt für 0€ handeln
01.06.NRDS, PTGX and SGMO are among after hour movers9
01.06.Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences311Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Jefferies Healthcare Conference Date:...
► Artikel lesen
25.05.SANGAMO THERAPEUTICS, INC - 8-K, Current Report11
06.05.Sangamo Therapeutics stock slips despite Q1 revenue beat33
05.05.SANGAMO THERAPEUTICS, INC - 8-K, Current Report17
05.05.Sangamo Therapeutics GAAP EPS of -$0.30 beats by $0.01, revenue of $28.23M beats by $0.94M14
02.05.Sangamo Therapeutics, Inc.: Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)343Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation...
► Artikel lesen
29.03.Sangamo begins dosing in trial of TX200 for preventing kidney transplant rejection31
23.03.ADPT, SGMO and RDBX among after hour movers21
25.02.Sangamo Therapeutics rises 5% after hours following Q4 earnings27
08.02.Sangamo Therapeutics Shares Updated Interim Data From Fabry Disease Gene Therapy Trial19
08.02.Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease525Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients - In the first two dose cohorts, all four patients exhibited...
► Artikel lesen
04.02.Sanofi ends two phase 1 cancer assets weeks after axing Sangamo deal22
06.01.Sanofi's overhaul of genomic medicines strategy spells end of Sangamo alliance43
06.01.Sangamo's sickle cell alliance with Sanofi grinds to a halt as pharma giant switches focus to allo21
06.01.Sangamo Says Sanofi To Transition Sickle Cell Disease Program Back To Sangamo630PARIS (dpa-AFX) - Genomic medicines company Sangamo Therapeutics, Inc. (SGMO) announced Thursday that French drug major Sanofi (SNYNF, SNY) will be transitioning its rights and obligations related...
► Artikel lesen
06.01.Sanofi terminates collaboration with Sangamo for sickle cell disease program14
06.01.Sanofi tears up Sangamo cell therapy deal in pivot to off-the-shelf approaches16
06.01.Berkeley Lights, Sangamo Therapeutics, MicroVision among premarket losers' pack33
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,7